In Reply to Tallet et al

To the Editor: We would like to thank Dr Tallet and colleagues for their letter regarding our article on the clinical outcomes of RapidArc versus tomotherapy for patients with head and neck cancer (1). We showed that patients in the group treated with tomotherapy had better local control and cancer-specific survival, but no difference was found on overall and progression-free survival. We agree with the authors that variability in delineation and patient positioning might have contributed to the differences we showed in our analysis of the prospective trial ART-ORL (Advanced Radiotherapy Oto-Rhino-Laryngologie) (2).

http://ift.tt/2m74Uw3